Compare iShares Gold Trust (IAU) vs Eli Lilly And Co (LLY) Price & Performance

IAU, the iShares Gold Trust ETF, trades at $75.35, down 0.2% on the day. Technical indicators are bearish, with moving averages signaling a downtrend and key support at $75. Recent news highlights institutional activity, including a new position by Eurizon Asset Management Hungary Ltd. in Q1 2026, while broader gold sentiment is pressured by expectations of sustained higher interest rates.

The outlook for IAU is influenced by macroeconomic factors affecting gold. Higher-for-longer interest rate expectations from the Fed (WSJ, 2026-07-19) pose a headwind, but structural central bank buying (WSJ, 2026-07-16) offers support. The primary risk is gold's sensitivity to monetary policy, while the opportunity lies in its role as a hedge amid economic uncertainty.

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.